Gergen Mark J 4
4 · Poseida Therapeutics, Inc. · Filed Jan 4, 2024
Insider Transaction Report
Form 4
Gergen Mark J
DirectorExecutive Chairman
Transactions
- Award
Stock Option (Right to buy)
2024-01-02+172,600→ 172,600 totalExercise: $3.38Exp: 2034-01-01→ Common Stock (172,600 underlying) - Award
Common Stock
2024-01-02+125,000→ 732,610 total
Footnotes (3)
- [F1]Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest 50% on each of the one-year and two-year anniversary of January 1, 2024.
- [F2]Includes 3,000 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on March 20, 2023 and 3,000 shares acquired by the Reporting Person under the ESPP on September 20, 2023.
- [F3]25% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of January 1, 2024, and the remaining shares will vest in 18 equal monthly installments thereafter.